Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production. It is available in oral and intravenous formulations.
## Primary Indications
* Gastroesophageal reflux disease (GERD)
* Healing of erosive esophagitis
* Treatment of Duodenal Ulcers
* Treatment of Gastric Ulcers
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome)
## Adult Dosing
* **GERD (symptomatic relief):** 20 mg orally once daily. May increase to 40 mg once daily if needed.
* **Healing of erosive esophagitis:** 40 mg orally once daily for 4 to 8 weeks.
* **Maintenance of healing of erosive esophagitis:** 20 mg orally once daily.
* **Duodenal Ulcers:** 40 mg orally once daily for 2 to 4 weeks.
* **Gastric Ulcers:** 40 mg orally once daily for 4 to 8 weeks.
* **Pathological hypersecretory conditions:** Starting dose typically 40 mg orally or IV twice daily. Doses can be escalated based on clinical response. Maximum daily dose is generally 240 mg.
## Pediatric Dosing
* **GERD (age 5 years and older):**
* Healing of erosive esophagitis: 40 mg orally once daily for 4 to 8 weeks.
* Symptomatic treatment of GERD: 20 mg orally once daily for up to 8 weeks.
* **Note:** Dosing for children younger than 5 years is not well-established and should be based on clinical judgment and available guidelines. IV formulations are generally not recommended in pediatric patients.
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 40 mg orally or IV once daily.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
* **Common:** Diarrhea, headache, dizziness, abdominal pain, nausea, vomiting.
* **Long-term use concerns:** Increased risk of C. difficile-associated diarrhea, bone fractures (hip, wrist, spine), vitamin B12 deficiency, and hypomagnesemia.
## Key Drug Interactions
* **Clopidogrel:** Pantoprazole may decrease the efficacy of clopidogrel. Concomitant use should be approached with caution, particularly in high-risk patients.
* **Methotrexate:** PPIs can increase methotrexate levels. Consider temporary discontinuation of pantoprazole if high-dose methotrexate is used.
* **Drugs affected by gastric pH:** Ketoconazole, itraconazole, iron salts, and mycophenolate mofetil absorption may be decreased.
## Monitoring
* Magnesium levels, especially with long-term use or concurrent diuretic use.
* Bone mineral density screening may be considered in patients at risk for osteoporosis.
* Clinical response for the condition being treated.
## Clinical Pearls
* Oral pantoprazole should be taken at least 1 hour before a meal for optimal efficacy.
* Pantoprazole delayed-release tablets and pantoprazole sodium for injection are generally not interchangeable on a mg-per-mg basis due to different bioavailabilities.
* IV pantoprazole should be infused over 15 minutes or longer.
* Re-evaluate the need for PPI therapy periodically, especially for indications other than healing of erosive esophagitis.
***
*This information is intended for healthcare professionals. Please consult the current prescribing information for complete details and to verify dosage and safety information before making clinical decisions.*
